Table 2 Characteristics of the patients in each age-group
Age group | 30-60 days | 61-90 days | >90 days | P |
|---|---|---|---|---|
Number of patients (male/female) | 25(15/10) | 11(7/4) | 7(4/3) | |
CMV copies/mL in plasma, Median (IQR) | 140(30-200)x 103 copies/mL | 90(42-200) x 103 copies/mL | 50(25-60) x 103 copies/mL | 0.22 |
CMV copies/mL in tracheal aspirates, Median (IQR) | 66.9(5-396)x 103 copies/mL | 185(122-900) x 103 copies/mL | 212(15-410) x 103 copies/mL) | 0.53 |
SpO2 on admission, Median (IQR) | 88(85-89)% | 89(84-92)% | 90(86-92)% | 0.08 |
Oxygen treatment duration , Median (IQR) | 12(6-22)days | 7(0-13)days | 9(0-22)days | 0.29 |
GCV treatment duration , Median (IQR) * | 13 (9-17)days | 14(10-17)days | 8(7-10) days | 0.013* |
Percentage of the patients with low IgG (IgG < 176 mg/dl)* | 20% | 33% | 33% | 0.02* |
Percentage of the patients with low CD4 (CD4 < 35%)* | 81% | 56% | 50% | 0.001* |